EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 572 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Rilzabrutinib
CAS:<p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Forma y color:SolidPeso molecular:665.76Petosemtamab
CAS:<p>Petosemtamab (MCLA 158), a dual-action monoclonal antibody targets EGFR & LGR5, used in solid tumor research like HNSCC & CRC.</p>Pureza:> 95% - > 95%Forma y color:LiquidPeso molecular:145.97 kDaLosatuxizumab
CAS:<p>Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody with potential anti-tumor activity for the study of advanced malignant solid tumors.</p>Pureza:97.3% (SDS-PAGE); 95.1% (SEC-HPLC) - 97.3% (SDS-PAGE); 95.1% (SEC-HPLC)Forma y color:LiquidMutated EGFR-IN-1
CAS:<p>Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating</p>Fórmula:C25H31N7OPureza:98.91%Forma y color:SolidPeso molecular:445.56Gefitinib
CAS:<p>Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations.</p>Fórmula:C22H24ClFN4O3Pureza:99.92% - >99.99%Forma y color:Light-Yellow Crystalline PowderPeso molecular:446.9Rociletinib
CAS:<p>Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic</p>Fórmula:C27H28F3N7O3Pureza:98.52% - 99.25%Forma y color:SolidPeso molecular:555.55Barecetamab
CAS:<p>Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity.</p>Pureza:97.1% (SDS-PAGE); 96.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidErlotinib
CAS:<p>Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.</p>Fórmula:C22H23N3O4Pureza:98.19% - 99.98%Forma y color:White To Off-White PowderPeso molecular:393.44N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine
CAS:Fórmula:C29H26ClFN4O4SPureza:98%Forma y color:SolidPeso molecular:581.0575Ref: IN-DA0039KT
1g106,00€5g222,00€50g573,00€100gA consultar250gA consultar25mg29,00€100mg44,00€250mg56,00€Methyl 2,5-Dihydroxycinnamate
CAS:Fórmula:C10H10O4Pureza:95%Forma y color:SolidPeso molecular:194.1840Propanedinitrile,2-[(4-methoxyphenyl)methylene]-
CAS:Fórmula:C11H8N2OPureza:98%Forma y color:SolidPeso molecular:184.1940HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Fórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Fórmula:C24H25BrN6O2Forma y color:SolidPeso molecular:509.408MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Fórmula:C52H72N12O11Pureza:97.70%Forma y color:SolidPeso molecular:1041.2Pertuzumab
CAS:<p>Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2</p>Pureza:98.00%Forma y color:LiquidPeso molecular:148 kDaTephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Fórmula:C23H22O7Pureza:98%Forma y color:SolidPeso molecular:410.42Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Pureza:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidEGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Fórmula:C50H55ClFN5O5Forma y color:SolidPeso molecular:860.45DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Forma y color:Odour SolidDP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Forma y color:LiquidWAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C22H19N3O3Pureza:98.05%Forma y color:SolidPeso molecular:373.4EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SForma y color:SolidPeso molecular:916.06IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Forma y color:Odour LiquidEGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Fórmula:C49H53ClFN5O5Forma y color:SolidPeso molecular:846.43Gefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Fórmula:C22H24ClFN4O41·5HClForma y color:SolidPeso molecular:517.59YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Forma y color:Odour LiquidTimigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Forma y color:LiquidDS06652923
<p>DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.</p>Forma y color:Odour SolidDepatuxizumab MMAF
<p>Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.</p>Forma y color:LiquidPeso molecular:148.24 kDaJAK 3 inhibitor IV
CAS:<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Fórmula:C16H19NOPureza:98%Forma y color:SolidPeso molecular:241.33Istiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Forma y color:LiquidZenocutuzumab
CAS:<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Pureza:97%Forma y color:LiquidBMS-599626
CAS:<p>BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.</p>Fórmula:C27H27FN8O3Pureza:98.73%Forma y color:SolidPeso molecular:530.55PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78PROTAC EGFR degrader 3
CAS:<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Fórmula:C60H77N13O5SForma y color:SolidPeso molecular:1092.4EGFR T790M/L858R-IN-6
CAS:<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>Fórmula:C27H27N7O2Forma y color:SolidPeso molecular:481.55AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Forma y color:SolidPeso molecular:352.21MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Fórmula:C50H59ClF4N8O14Forma y color:SolidPeso molecular:1107.5EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Fórmula:C27H37FN8O2Forma y color:SolidPeso molecular:524.633EGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSForma y color:SolidPeso molecular:490.98AZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Fórmula:C23H15ClF2N6O2Forma y color:SolidPeso molecular:480.854Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Fórmula:C25H27Cl2FN4O4Forma y color:SolidPeso molecular:537.41HDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Fórmula:C17H11ClFN5OForma y color:SolidPeso molecular:355.76EGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Forma y color:Odour SolidDSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Forma y color:Odour SolidEGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Forma y color:Odour SolidCetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Forma y color:Odour LiquidInetetamab
<p>Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.</p>Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Forma y color:Odour LiquidGW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Fórmula:C28H25ClFN5O3S2Pureza:98.68%Forma y color:SoildPeso molecular:598.11PROTAC EGFR degrader 10
CAS:<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>Fórmula:C49H65ClN10O7SForma y color:SolidPeso molecular:973.62
![N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA0039KT.webp&w=3840&q=75)
![Propanedinitrile,2-[(4-methoxyphenyl)methylene]-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA007L0Q.webp&w=3840&q=75)
